Assessment of HER-2/neu Status in Breast Cancer Automated Cellular Imaging System (ACIS)-Assisted Quantitation of Immunohistochemical Assay Achieves High Accuracy in Comparison With Fluorescence In Situ Hybridization Assay as the Standard

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays

  2000cited by this paper
• HER-2/neu Testing in Breast Carcinoma: A Combined Immunohistochemical and Fluorescence In Situ Hybridization Approach

  2000cited by this paper
• HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma.

  2000cited by this paper
• Testing for erbB-2 by immunohistochemistry in breast cancer.

  2000cited by this paper
• Strong Correlation between Results of Fluorescent In Situ Hybridization and Immunohistochemistry for the Assessment of the ERBB2 (HER-2/neu) Gene Status in Breast Carcinoma

  2000cited by this paper
• Immunohistochemical determination of HER-2/neu expression in invasive breast carcinoma.

  2000cited by this paper
• Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry.

  2000cited by this paper
• Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer.

  1999cited by this paper
• Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.

  1998cited by this paper
• Prognostic and predictive factors in breast cancer by immunohistochemical analysis.

  1998cited by this paper
• Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anti-cancer activity: a randomised multinational controlled phase III trial

  1998cited by this paper
• ERBB2 oncogene in human breast cancer and its clinical significance.

  1998cited by this paper
• Rapid and prognostically valid quantification of immunohistochemical reactions by immunohistometry of the most positive tumour focus. A prospective follow‐up study on breast cancer using antibodies against MIB‐1, PCNA, ER, and PR

  1998cited by this paper
• The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand‐receptor interactions

  1997cited by this paper
• HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.

  1997cited by this paper
• HER‐2/neu Signal Transduction in Human Breast and Ovarian Cancer

  1997cited by this paper
• The prognostic value of c-erbB2 in primary breast carcinomas: A study on 942 cases

  1995cited by this paper
• Quantitative immunohistochemical assay for hormonal receptors: technical aspects and biological significance.

  1994cited by this paper
• Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

  1992cited by this paper
• ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization.

  1992cited by this paper
• Humanization of an anti-p185HER2 antibody for human cancer therapy.

  1992cited by this paper
• Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer.

  1991cited by this paper
• Strategies for the analysis of oncogene overexpression. Studies of the neu oncogene in breast carcinoma.

  1990cited by this paper
• Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32.

  1989cited by this paper
• Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

  1987cited by this paper
• Applied multiple regression/correlation analysis for the behavioral sciences

  1979cited by this paper
• STATISTICS: AN INTRODUCTION.

  1965cited by this paper

• HER2/Neu Distribution in Female Breast Cancer in Libya: Correlation with Clinicopathological Features and Survival

  2021cites this paper
• HER2 Testing in the Era of Changing Guidelines

  2019cites this paper
• Novel Prognostic and Predictive Markers for Canine Mast Cell Tumours

  2019cites this paper
• Intra-tumor molecular heterogeneity in breast cancer: definitions of measures and association with distant recurrence-free survival

  2018cites this paper
• Comparative study between quantitative digital image analysis and fluorescence in situ hybridization of breast cancer equivocal human epidermal growth factor receptors 2 score 2+ cases

  2015cites this paper
• Analysis of HER2 gene amplification using Differential PCR in breast cancer patients of Isfahan Province

  2014cites this paper
• Prospective analysis of Ki-67 as an independent predictor of oncologic outcomes in patients with high grade upper tract urothelial carcinoma.

  2014cites this paper
• Prognostication of Canine Mammary Carcinomas Based on Histological and Immunohistochemical Subtypes

  2014cites this paper
• HER2 in Breast Cancer: A Review and Update

  2014cites this paper
• Ki-67 Index as an Ancillary Tool in the Differential Diagnosis of Proliferative Endometrial Lesions With Secretory Change

  2014cites this paper
• Single-cell quantitative HER2 measurement identifies heterogeneity and distinct subgroups within traditionally defined HER2-positive patients.

  2013cites this paper
• Reproducibility in the automated quantitative assessment of HER2/neu for breast cancer

  2013cites this paper
• Quantification of protein expression in cells and cellular subcompartments on immunohistochemical sections using a computer supported image analysis system.

  2013cites this paper
• Her-2/neu overexpression is associated with thrombospondin-1-related angiogenesis and thrombospondin-1-unrelated lymphangiogenesis in breast cancer

  2013cites this paper
• Detection of HER2 Status in Breast Cancer: Comparison of &XUUHQW0HWKRGVZLWK0/3$DQG5HDOWLPH573&5

  2013cites this paper
• Grading of Well-differentiated Pancreatic Neuroendocrine Tumors Is Improved by the Inclusion of Both Ki67 Proliferative Index and Mitotic Rate

  2013cites this paper
• Diagnostic-Therapeutic Combinations

  2013cites this paper
• Detection of HER2 status in breast cancer: comparison of current methods with MLPA and real-time RT-PCR.

  2013cites this paper
• Genomic and proteomic analysis with dynamically growing self organising tree (DGSOT) for measuring clinical outcomes of cancer

  2012cites this paper
• Anatomic Pathology / Proliferative Index in Pancreatic Neuroendocrine Tumors

  2012cites this paper
• Quantitative assessment and classification of tissue-based biomarker expression with color content analysis.

  2012cites this paper
• Point: Fluorescence in situ hybridization is the preferred approach over immunohistochemistry for determining HER2 status.

  2011cites this paper
• Immunohistochemical expression of estrogen and progesterone receptors in human colorectal adenoma and carcinoma using specified automated cellular image analysis system: a clinicopathological study.

  2011cites this paper
• An analysis of HER-2/neu gene status in invasive ductal carcinomas using immunohistochemistry and fluorescence in situ hybridization

  2011cites this paper
• Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi‐institutional study

  2011cites this paper
• Clinical and health economic outcomes of alternative HER2 test strategies for guiding adjuvant trastuzumab therapy

  2011cites this paper
• Estrogen Receptor Expression in Atypical Hyperplasia: Lack of Association with Breast Cancer

  2011cites this paper
• Prognostic impact of MUM1 expression by immunohistochemistry on primary mediastinal large B-cell lymphoma

  2011cites this paper
• Observer variability in the interpretation of HER2/neu immunohistochemical expression with unaided and computer-aided digital microscopy.

  2011cites this paper
• Evaluación de tres métodos moleculares para el rastreo e identificación de HER2/neu en pacientes con cáncer de mama Evaluation of three molecular methods for tracking and identifying HER2/neu oncogene in breast cancer patients

  2010cites this paper
• ANÁLISE DE FATORES PROGNÓSTICOS E DA EXPRESSÃO IMUNOISTOQUIMICA DA INVOLUCRINA, E DAS PROTEÍNAS DA PLACA DESMOSSÔMICA: DESMOGLEINA, PLAKOGLOBINA E DESMOPLAKINA ATRAVÉS DA TÉCNICA DE "TISSUE MICROARRAY" EM PACIENTES

  2010cites this paper
• The application of cDNA and tissue microarray methods in the study of human carcinomas

  2010cites this paper
• Targeted Therapies for Cancer

  2010cites this paper
• Evaluación de tres métodos moleculares para el rastreo e identificación de HER2/neu en pacientes con cáncer de mama

  2010cites this paper
• Segmentation of Stained Lymphoma Tissue Section Images

  2010cites this paper
• Image analysis as an adjunct to manual HER-2 immunohistochemical review: a diagnostic tool to standardize interpretation

  2010cites this paper
• Automated cellular imaging system III for assessing HER2 status in breast cancer specimens: development of a standardized scoring method that correlates with FISH.

  2009cites this paper
• The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine.

  2009cites this paper
• Reply to V. Arena et al

  2009cites this paper
• CHAPTER 82 – Diagnostic-Therapeutic Combinations in the Treatment of Cancer

  2009cites this paper
• Her-2/neu status in breast cancer metastases to the central nervous system.

  2009cites this paper
• Reply to E.H. Hammond et al

  2009cites this paper
• Practice evolution: decentralized computer-assisted immunohistochemical image analysis.

  2009cites this paper
• Her-2/neu, P-53, and Their Coexpression in Osteosarcoma

  2009cites this paper
• Immunohistochemistry and quantitative analysis of protein expression.

  2009cites this paper
• Bladder Cancer-associated Protein, a Potential Prognostic Biomarker in Human Bladder Cancer*

  2009cites this paper
• Comparison of digital image analysis versus visual assessment to assess survivin expression as an independent predictor of survival for patients with clear cell renal cell carcinoma.

  2008cites this paper
• Comparison of Chromogenic In Situ Hybridisation with Fluorescence In Situ Hybridisation and Immunohistochemistry for the Assessment of Her-2/neu Oncogene in Archival Material of Breast Carcinoma

  2008cites this paper
• Antibody-based profiling of expression patterns using cell and tissue microarrays.

  2008cites this paper
• Co-Development of Drugs and Pharmacogenomics-Based Diagnostics in Oncology

  2008cites this paper
• Computer-assisted assessment of the Human Epidermal Growth Factor Receptor 2 immunohistochemical assay in imaged histologic sections using a membrane isolation algorithm and quantitative analysis of positive controls

  2008cites this paper
• Case Report: Effects of Image Compression on Automatic Count of Immunohistochemically Stained Nuclei in Digital Images

  2008cites this paper
• Genomics and proteomics in predicting cancer outcomes.

  2008cites this paper
• Virtual microscopy as an enabler of automated/quantitative assessment of protein expression in TMAs

  2008cites this paper
• American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

  2007cites this paper
• A Clinically Motivated 2-Fold Framework for Quantifying and Classifying Immunohistochemically Stained Specimens

  2007cites this paper
• Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness

  2007cites this paper
• Automated recognition of cell phenotypes in histology images based on membrane- and nuclei-targeting biomarkers

  2007cites this paper
• Standardization of HER2 testing: results of an international proficiency-testing ring study

  2007cites this paper
• Progesterone receptor expression is a marker for early stage breast cancer: implications for progesterone receptor as a therapeutic tool and target.

  2007cites this paper
• Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.

  2007cites this paper
• Telomerase and Markers of Cellular Proliferation Are Associated With the Progression of Cervical Intraepithelial Neoplasia Lesions

  2007cites this paper
• Expression of cyclooxygenase-2 in normal urothelium, and superficial and advanced transitional cell carcinoma of bladder.

  2007cites this paper
• Entropy and information content of laboratory test results.

  2007cites this paper
• Targeted therapy of breast cancer.

  2007cites this paper
• A high‐throughput strategy for protein profiling in cell microarrays using automated image analysis

  2007cites this paper
• Genomics and proteomics: emerging technologies in clinical cancer research.

  2007cites this paper
• Borderline HER‐2 breast cancer cases: Histochemical versus real‐time PCR analysis and impact of different cut‐off values

  2007cites this paper
• Survivin expression is associated with bladder cancer presence, stage, progression, and mortality

  2007cites this paper
• Adult Urology Survivin Expression in Patients with Non- Muscle-Invasive Urothelial Cell Carcinoma of the Bladder

  2007cites this paper
• DNA and Tissue Microarrays

  2007cites this paper
• Microarrays as Validation Strategies in Clinical Samples: Tissue and Protein Microarrays

  2006cites this paper
• Ki-67 Is an Independent Predictor of Bladder Cancer Outcome in Patients Treated with Radical Cystectomy for Organ-Confined Disease

  2006cites this paper
• Slow transit colon constipation is not related to the number of interstitial cells of Cajal

  2006influential citation
• Expression of Stress Response Protein Grp78 Is Associated with the Development of Castration-Resistant Prostate Cancer

  2006cites this paper
• HER 2 and TP 53 in human breast cancer Studies of methods and prognostic value

  2006cites this paper
• Comparison of immunohistochemistry by automated cellular imaging system (ACIS) versus fluorescence in‐situ hybridization in the evaluation of HER‐2/neu expression in primary breast carcinoma

  2006cites this paper
• Survivin expression is associated with bladder cancer presence, stage, progression, and mortality.

  2006cites this paper
• A survivin gene signature predicts aggressive tumor behavior. Salz W, Eisenberg D, Plescia J, Garlick DS, Weiss RM, Wu XR, Sun TT, Altieri DC, Department of Cancer Biology and the Cancer Center, University of Massachusetts Medical School, Worcester, MA

  2006cites this paper
• Quantification of immunohistochemistry—issues concerning methods, utility and semiquantitative assessment I

  2006cites this paper
• American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

  2006cites this paper
• HER2 and TP53 in human breast cancer : Studies of methods and prognostic value

  2006cites this paper
• Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas.

  2006cites this paper
• HER-2 Status in Breast Cancer: Correlation of Gene Amplification by FISH With Immunohistochemistry Expression Using Advanced Cellular Imaging System

  2006cites this paper
• EXPRESSION OF SURVIVIN AND APOPTOTIC BIOMARKERS IN BENIGN PROSTATIC HYPERPLASIA

  2006cites this paper
• Automation of Manual Components and Image Quantification of Direct Dual Label Fluorescence In Situ Hybridization (FISH) for HER2 Gene Amplification: A Feasibility Study

  2006cites this paper
• JNCCN HER 2 Testing in Breast Cancer : NCCN Task Force Report and Recommendations

  2006cites this paper
• Chapter 17 – Immunohistology of the Breast

  2006cites this paper
• TESTING FOR HER 2 POSITIVE BREAST CANCER : A COST-EFFECTIVENESS ANALYSIS Report

  2006cites this paper
• α-Methylacyl-CoA Racemase Protein Expression Is Associated with the Degree of Differentiation in Breast Cancer Using Quantitative Image Analysis

  2005cites this paper
• Tissue microarrays – automated analysis and future directions

  2005cites this paper
• Histomathematical Analysis of Clinical Specimens: Challenges and Progress

  2005cites this paper
• Central nervous system metastases in breast cancer patients administered trastuzumab.

  2005cites this paper
• Quantitative in situ cancer proteomics: molecular pathology comes of age with automated tissue microarray analysis.

  2005cites this paper
• Analysis of intratumoral heterogeneity and amplification status in breast carcinomas with equivocal (2+) HER-2 immunostaining.

  2005cites this paper
• Discordant Results Obtained for Different Methods of HER-2/Neu Testing in Breast Cancer – A Question of Standardization, Automation and Timing

  2004cites this paper
• HER-2/neu (c-erbB-2) Evaluation in Primary Breast Carcinoma by Fluorescent In Situ Hybridization and Immunohistochemistry With Special Focus on Intratumor Heterogeneity and Comparison of Invasive and In Situ Components

  2004influential citation
• Discordant results obtained for different methods of HER-2/neu testing in breast cancer--a question of standardization, automation and timing.

  2004cites this paper
• Enhanced accuracy and reliability of HER-2/neu immunohistochemical scoring using digital microscopy.

  2004cites this paper
• Breast cancer—the role of the pathologist and targeted therapies/optimal pathology reporting

  2004cites this paper